What is Fate Therapeutics Debt-to-Equity?
Fate Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $6.18 Mil. Fate Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $97.36 Mil. Fate Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $368.42 Mil.
Fate Therapeutics's debt to equity for the quarter that ended in Dec. 2023 was 0.28.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Fate Therapeutics's Debt-to-Equity or its related term are showing as below:
FATE'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.09 Med: 0.21 Max: 0.69
Current: 0.28
During the past 13 years, the highest Debt-to-Equity Ratio of Fate Therapeutics was 0.69. The lowest was 0.09. And the median was 0.21.
Fate Therapeutics Debt-to-Equity Historical Data
The historical data trend for Fate Therapeutics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fate Therapeutics Debt-to-Equity Chart
|
Fate Therapeutics Annual Data
|
|
Trend |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Debt-to-Equity |
|
Get a 7-Day Free Trial
|
|
|
0.11 |
0.25 |
0.17 |
0.23 |
0.28 |
|
Fate Therapeutics Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Debt-to-Equity |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
0.23 |
0.23 |
0.24 |
0.26 |
0.28 |
Competitive Comparison of Fate Therapeutics's Debt-to-Equity
For the Biotechnology subindustry, Fate Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fate Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fate Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Fate Therapeutics's Debt-to-Equity falls into.
Fate Therapeutics Debt-to-Equity Calculation
Debt to Equity measures the financial leverage a company has.
Fate Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Fate Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fate Therapeutics (Fate Therapeutics) Business Description
Traded in Other Exchanges
Address
12278 Scripps Summit Drive, San Diego, CA, USA, 92131
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and immune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Executives
| J Scott Wolchko |
director, officer: President and CEO |
C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121 |
| Dulac Edward J Iii |
officer: Chief Financial Officer |
FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT STE 200, SAN DIEGO CA 92121 |
| Bahram Valamehr |
officer: Chief Development Officer |
C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, STE 200, SAN DIEGO CA 92121 |
| Cindy Tahl |
officer: See Remarks |
C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, STE 200, SAN DIEGO CA 92121 |
| Redmile Group, Llc |
director, 10 percent owner |
ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129 |
| Yuan Xu |
director |
C/O AKERO THERAPEUTICS, INC., 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO CA 94080 |
| Brian T. Powl |
officer: Chief Commercial Officer |
C/O FATE THERAPEUTICS, INC., 12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO CA 92131 |
| Yu-waye Chu |
officer: See Remarks |
FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT STE 200, SAN DIEGO CA 92121 |
| John Mendlein |
director |
|
| Mark Plavsic |
officer: Chief Technical Officer |
C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT STE 200, SAN DIEGO CA 92121 |
| Shefali Agarwal |
director |
C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
| Karin Jooss |
director |
C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608 |
| Timothy P Coughlin |
director |
339 NORTH GRANADOS AVE, SOLANA BEACH CA 92075 |
| Robert Hershberg |
director |
3005 FIRST AVENUE, SEATTLE WA 98121 |
| Robert S Epstein |
director |
|
Fate Therapeutics (Fate Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FATE has been successfully added to your